Literature DB >> 3944585

Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses.

M W Brandriss, J J Schlesinger, E E Walsh, M Briselli.   

Abstract

Monoclonal antibodies to the envelope proteins (E) of the 17D vaccine strain of yellow fever virus (17D YF) and to dengue 2 virus were examined for their ability to confer passive protection against lethal 17D YF encephalitis in mice. All 13 IgG anti-17D YF antibodies, regardless of neutralizing capacity, conferred solid protection when given in a relatively high dose prior to intracerebral inoculation of virus. Three antibodies with high in vitro neutralizing titres were all protective at a low dose as were several non-neutralizing antibodies. One flavivirus group-reactive antibody to dengue 2 virus conferred similar protection at low dose. Protection was also observed when antibodies were given several days after virus inoculation when peak infectious virus titres and histopathological evidence of infection were present in brains. The ability of a non-neutralizing antibody to protect could not be attributed to complement-dependent lysis of virus-infected cells and did not correlate with avidity or with proximity of its binding site to a critical neutralizing epitope of the E protein. Some antibodies, characterized as non-neutralizing by plaque reduction assay on Vero cells, inhibited the growth of virus in a mouse neuroblastoma cell line, suggesting one possible mechanism of protection. These results may be relevant to the design of prospective flavivirus vaccines and support the possibility of conferring broadened protection among flaviviruses by stimulating the antibody response to appropriate epitopes of the E protein.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3944585     DOI: 10.1099/0022-1317-67-2-229

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  41 in total

1.  Hemagglutinin-esterase-specific monoclonal antibodies alter the neuropathogenicity of mouse hepatitis virus.

Authors:  K Yokomori; S C Baker; S A Stohlman; M M Lai
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

2.  Identification of novel target sites and an inhibitor of the dengue virus E protein.

Authors:  Ragothaman Yennamalli; Naidu Subbarao; Thorsten Kampmann; Ross P McGeary; Paul R Young; Bostjan Kobe
Journal:  J Comput Aided Mol Des       Date:  2009-02-25       Impact factor: 3.686

3.  Epitope mapping of dengue 1 virus E glycoprotein using monoclonal antibodies.

Authors:  E Simantini; K Banerjee
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

4.  Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.

Authors:  Justin G Julander; Dennis W Trent; Thomas P Monath
Journal:  Vaccine       Date:  2011-06-28       Impact factor: 3.641

5.  Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein.

Authors:  T R Kreil; E Maier; S Fraiss; M M Eibl
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

6.  Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins.

Authors:  Eddie A James; Rebecca E LaFond; Theresa J Gates; Duy T Mai; Uma Malhotra; William W Kwok
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

7.  Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.

Authors:  F Guirakhoo; K Pugachev; Z Zhang; G Myers; I Levenbook; K Draper; J Lang; S Ocran; F Mitchell; M Parsons; N Brown; S Brandler; C Fournier; B Barrere; F Rizvi; A Travassos; R Nichols; D Trent; T Monath
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus.

Authors:  Ruhe Men; Tetsu Yamashiro; Ana P Goncalvez; Claire Wernly; Darren J Schofield; Suzanne U Emerson; Robert H Purcell; Ching-Juh Lai
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

9.  The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.

Authors:  Bimmi Shrestha; James D Brien; Soila Sukupolvi-Petty; S Kyle Austin; Melissa A Edeling; Taekyung Kim; Katie M O'Brien; Christopher A Nelson; Syd Johnson; Daved H Fremont; Michael S Diamond
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823

10.  Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses.

Authors:  Denis Gaucher; René Therrien; Nadia Kettaf; Bastian R Angermann; Geneviève Boucher; Abdelali Filali-Mouhim; Janice M Moser; Riyaz S Mehta; Donald R Drake; Erika Castro; Rama Akondy; Aline Rinfret; Bader Yassine-Diab; Elias A Said; Younes Chouikh; Mark J Cameron; Robert Clum; David Kelvin; Roland Somogyi; Larry D Greller; Robert S Balderas; Peter Wilkinson; Giuseppe Pantaleo; Jim Tartaglia; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  J Exp Med       Date:  2008-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.